New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
作者： Giuseppe Danilo Norata , Christie M Ballantyne , Alberico Luigi Catapano , None
关键词:
摘要: Dyslipidaemias play a key role in determining cardiovascular risk; the discovery of statins has contributed very effective approach. However, many patients do not achieve, at maximal tolerated dose, recommended goals for low-density lipoprotein-cholesterol (LDL-C), non-high-density lipoprotein-cholesterol, and apolipoprotein B (apoB). Available agents combined with can provide additional LDL-C reduction, development will increase therapeutic options impacting also other atherogenic lipoprotein classes. In fact, genetic insights into mechanisms underlying regulation levels expanded potential targets drug therapy led to novel agents. Among them are modulators apoB containing lipoproteins production proprotein convertase subtilisin/kexin type-9 inhibitors. Alternative such as lipoprotein(a) require attention; however, until we have better understanding these issues, further lowering high high-risk represent most sound clinical
oup.com
elsevier.com
curtin.edu.au
oxfordjournals.org参考文章(52)
Clapton S. Dias, Adam J. Shaywitz, Scott M. Wasserman, Brian P. Smith, Bing Gao, Dina S. Stolman, Caroline P. Crispino, Karen V. Smirnakis, Maurice G. Emery, Alexander Colbert, John P. Gibbs, Marc W. Retter, Blaire P. Cooke, Stephen T. Uy, Mark Matson, Evan A. Stein, Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. Journal of the American College of Cardiology. ,vol. 60, pp. 1888- 1898 ,(2012) , 10.1016/J.JACC.2012.08.986
Alberico Catapano, Combination therapy in cholesterol reduction: focus on ezetimibe and statins Vascular Health and Risk Management. ,vol. 4, pp. 267- 278 ,(2008) , 10.2147/VHRM.S1204
Frederick J Raal, Raul D Santos, Dirk J Blom, A David Marais, Min-Ji Charng, William C Cromwell, Robin H Lachmann, Daniel Gaudet, Ju L Tan, Scott Chasan-Taber, Diane L Tribble, JoAnn D Flaim, Stanley T Crooke, Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. The Lancet. ,vol. 375, pp. 998- 1006 ,(2010) , 10.1016/S0140-6736(10)60284-X
, Z. Reiner, A. L. Catapano, G. De Backer, I. Graham, M.-R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M. J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P. P. Filardi, G. Riccardi, R. F. Storey, D. Wood, J. Bax, A. Vahanian, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, G. Filippatos, C. Funck-Brentano, D. Hasdai, R. Hobbs, A. Hoes, P. Kearney, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, P. Vardas, P. Widimsky, S. Windecker, D. Reviewers:, C. Funck-Brentano, D. Poldermans, G. Berkenboom, J. De Graaf, O. Descamps, N. Gotcheva, K. Griffith, G. F. Guida, S. Gulec, Y. Henkin, K. Huber, Y. A. Kesaniemi, J. Lekakis, A. J. Manolis, P. Marques-Vidal, L. Masana, J. McMurray, M. Mendes, Z. Pagava, T. Pedersen, E. Prescott, Q. Rato, G. Rosano, S. Sans, A. Stalenhoef, L. Tokgozoglu, M. Viigimaa, M. E. Wittekoek, J. L. Zamorano, , , ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)☆☆☆ Atherosclerosis. ,vol. 32, pp. 1769- 1818 ,(2011) , 10.1093/EURHEARTJ/EHR158
Giuseppe Danilo Norata, Gianpaolo Tibolla, Alberico Luigi Catapano, None, Gene silencing approaches for the management of dyslipidaemia. Trends in Pharmacological Sciences. ,vol. 34, pp. 198- 205 ,(2013) , 10.1016/J.TIPS.2013.01.010
Christie M. Ballantyne, Michael Davidson, Diane MacDougall, Janice Margulies, Lorenzo DiCarlo, ETC-1002 LOWERS LDL-C AND BENEFICIALLY MODULATES OTHER CARDIO-METABOLIC RISK FACTORS IN HYPERCHOLESTEROLEMIC SUBJECTS WITH EITHER NORMAL OR ELEVATED TRIGLYCERIDES Journal of the American College of Cardiology. ,vol. 59, ,(2012) , 10.1016/S0735-1097(12)61626-X
Evan A. Stein, Scott Mellis, George D. Yancopoulos, Neil Stahl, Douglas Logan, William B. Smith, Eleanor Lisbon, Maria Gutierrez, Cheryle Webb, Richard Wu, Yunling Du, Therese Kranz, Evelyn Gasparino, Gary D. Swergold, Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol The New England Journal of Medicine. ,vol. 366, pp. 1108- 1118 ,(2012) , 10.1056/NEJMOA1105803
Pia R. Kamstrup, Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction JAMA. ,vol. 301, pp. 2331- 2339 ,(2009) , 10.1001/JAMA.2009.801
G.D. Norata, A.L. Catapano, Lipid lowering activity of drugs affecting cholesterol absorption. Nutrition Metabolism and Cardiovascular Diseases. ,vol. 14, pp. 42- 51 ,(2004) , 10.1016/S0939-4753(04)80046-2
Ingar Holme, Kurt Boman, Philippe Brudi, Kenneth Egstrup, Christa Gohlke-Baerwolf, Y. Antero Kesäniemi, William Malbecq, Anne B. Rossebø, Kristian Wachtell, Ronnie Willenheimer, Terje R. Pedersen, Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial American Journal of Cardiology. ,vol. 105, pp. 1802- 1808 ,(2010) , 10.1016/J.AMJCARD.2010.01.363